Bridger Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bridger Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-422,254	Closed	-$66M	–	49
2020 Q4	$66M	Buy	422,254 +43,800	+12%	+$5.63M	5.03%	5
2020 Q3	$43.3M	Buy	+378,454	New	+$40.8M	3.46%	11
2019 Q1	–	Sell	-200,049	Closed	-$19.5M	–	36
2018 Q4	$19.5M	Buy	+200,049	New	+$23.6M	1.62%	25
2018 Q2	–	Sell	-92,074	Closed	-$10.3M	–	41
2018 Q1	$10.3M	Buy	+92,074	New	+$11M	0.62%	35
2017 Q4	–	Sell	-555,120	Closed	-$77.9M	–	38
2017 Q3	$77.9M	Buy	555,120 +349,114	+169%	+$47.4M	4.66%	4
2017 Q2	$25.1M	Buy	+206,006	New	+$24M	1.43%	30

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridger Management's ALXN Position: Q1 2021 in Review

Bridger Management sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 422,254 shares — an estimated $66M sold.

Bridger Management first reported a position in ALXN in Q2 2017 and held it in 6 quarters. The position peaked at $77.9M in Q3 2017. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

Bridger Management reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Bridger Management sold 422,254 Alexion Pharmaceuticals shares in Q1 2021, an estimated $66M.
Bridger Management first reported a position in Alexion Pharmaceuticals in Q2 2017 and held it in 6 quarters.
Bridger Management's Alexion Pharmaceuticals position peaked at $77.9M in Q3 2017.
754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Bridger Management's 13F filing for Q1 2021, filed 14 May 2021.